Chondroitin sulfate is a sulfated glycosaminoglycan (GAG) composed of a chain of alternating sugars (N-acetylgalactosamine and glucuronic acid). It is usually found attached to proteins as part of a proteoglycan. A chondroitin chain can have over 100 individual sugars, each of which can be sulfated in variable positions and quantities. Chondroitin sulfate is an important structural component of cartilage and provides much of its resistance to compression. Along with glucosamine, chondroitin sulfate has become a widely used dietary supplement for treatment of osteoarthritis.
Chondroitin is used in dietary supplements as an alternative medicine to treat osteoarthritis and also approved and regulated as a symptomatic slow-acting drug for this disease (SYSADOA) in Europe and some other countries. It is commonly sold together with glucosamine. A 2015 Cochrane review of clinical trials found that most were of low quality, but that there was some evidence of short-term improvement in pain and few side effects; it does not appear to improve or maintain the health of affected joints.
Chondroitin, along with commonly used glucosamine, should not be used to treat people who have symptomatic osteoarthritis of the knee as evidence shows that these treatments fail to provide relief for that condition.
Clinical studies have not identified any significant side effects or overdoses of chondroitin sulfate, which suggest its long-term safety. In 2003 the Task Force of the European League Against Rheumatism (EULAR) committee ranked the level of toxicity of chondroitin sulfate 6 in a 0-100 scale.
Mechanisms of actionEdit
The effect of chondroitin sulfate in people with osteoarthritis is likely the result of a number of reactions including its anti-inflammatory activity, the stimulation of the synthesis of proteoglycans and hyaluronic acid, and the decrease in catabolic activity of chondrocytes inhibiting the synthesis of proteolytic enzymes, nitric oxide, and other substances that contribute to damage cartilage matrix and cause death of articular chondrocytes. A recent review summarizes data from relevant reports describing the biochemical basis of the effect of chondroitin sulfate on osteoarthritis articular tissues.
Bioavailability and pharmacokineticsEdit
Pharmacokinetic studies performed on humans and experimental animals after oral administration of chondroitin sulfate revealed that it can be absorbed orally. Chondroitin sulfate shows first-order kinetics up to single doses of 3,000 mg. Multiple doses of 800 mg in people with osteoarthritis do not alter the kinetics of chondroitin sulfate. The bioavailability of chondroitin sulfate ranges from 15% to 24% of the orally administered dose. More particularly, on the articular tissue, Ronca et al. reported that chondroitin sulfate is not rapidly absorbed in the gastro-intestinal tract and a high content of labeled chondroitin sulfate is found in the synovial fluid and cartilage.
Physical and chemical propertiesEdit
Chondroitin sulfate chains are unbranched polysaccharides of variable length containing two alternating monosaccharides: D-glucuronic acid (GlcA) and N-acetyl-D-galactosamine (GalNAc). Some GlcA residues are epimerized into L-iduronic acid (IdoA); the resulting disaccharide is then referred to as dermatan sulfate.
Chondroitin sulfate chains are linked to hydroxyl groups on serine residues of certain proteins. Exactly how proteins are selected for attachment of glycosaminoglycans is not understood. Glycosylated serines are often followed by a glycine and have neighboring acidic residues, but this motif does not always predict glycosylation.
Attachment of the GAG chain begins with four monosaccharides in a fixed pattern: Xyl - Gal - Gal - GlcA. Each sugar is attached by a specific enzyme, allowing for multiple levels of control over GAG synthesis. Xylose begins to be attached to proteins in the endoplasmic reticulum, while the rest of the sugars are attached in the Golgi apparatus.
Chondroitin sulfate was originally isolated well before the structure was characterised, leading to changes in terminology with time. Early researchers identified different fractions of the substance with letters.
|Letter identification||Site of sulfation||Systematic name|
|Chondroitin sulfate A||carbon 4 of the N-acetylgalactosamine (GalNAc) sugar||chondroitin-4-sulfate|
|Chondroitin sulfate C||carbon 6 of the GalNAc sugar||chondroitin-6-sulfate|
|Chondroitin sulfate D||carbon 2 of the glucuronic acid and 6 of the GalNAc sugar||chondroitin-2,6-sulfate|
|Chondroitin sulfate E||carbons 4 and 6 of the GalNAc sugar||chondroitin-4,6-sulfate|
Chondroitin, without the "sulfate", has been used to describe a fraction with little or no sulfation. However, this distinction is not used by all.
Although the name "chondroitin sulfate" suggests a salt with a sulfate counter-anion, this is not the case, as sulfate is covalently bonded to the sugar. Rather, since the molecule has multiple negative charges at physiological pH, a cation is present in salts of chondroitin sulfate. Commercial preparations of chondroitin sulfate typically are the sodium salt. Barnhill et al. have suggested that all such preparations of chondroitin sulfate be referred to as "sodium chondroitin" regardless of their sulfation status.
Clinical trials for osteoarthritisEdit
In 2004, a petition was submitted to the FDA that a dietary supplement of chondroitin sulfate be labeled as reducing the risk of osteoarthritis, cartilage deterioration, and osteoarthritis-related joint pain, tenderness, and swelling. The FDA denied the request, stating that experiments conducted by the company did not sufficiently demonstrate the effectiveness of the claim. Among other comments, the FDA noted the poor experimental design of some trials.
In 2007, Reichenbach et al. used explicit methods to conduct and report a systematic review of 20 trials and concluded "large-scale, methodologically sound trials indicate that the symptomatic benefit of chondroitin is minimal or nonexistent. Use of chondroitin in routine clinical practice should therefore be discouraged." In contrast, and also in 2007, Bruyere et al. concluded that "there is compelling evidence that glucosamine sulfate and chondroitin sulfate may interfere with progression of OA."
As of 2015 the largest trial conducted with the product was the Glucosamine and Chondroitin Arthritis Intervention Trial (GAIT), a double-blind, randomized, multicenter clinical trial sponsored by the US National Institutes of Health in 1583 people with knee osteoarthritis, which was published in the New England Journal of Medicine in 2006. Subjects were randomly assigned to one of five orally administered treatments: two 250 mg capsules of glucosamine hydrochloride three times daily, two 200 mg capsules of chondroitin sulphate three times daily, two capsules of 250 mg of glucosamine hydrochloride plus 200 mg of chondroitin sulphate three times daily, 200 mg of celecoxib daily, or placebo. Treatment was administered for 24 weeks. It showed no difference from placebo.
Sawitzke A, et al. 2010 evaluated the efficacy and safety of glucosamine and chondroitin sulfate, alone or in combination, as well as celecoxib and placebo on painful knee osteoarthritis over 2 years as a continuation of the GAIT trial. This was a 24-month, double-blind, placebo-controlled study, enrolling 662 people with knee osteoarthritis who satisfied radiographic criteria (Kellgren/Lawrence grade 2 or 3 changes and baseline joint space width of at least 2 mm). This subset continued to receive their randomized treatment (glucosamine 500 mg three times daily, chondroitin sulfate 400 mg three times daily, the combination of glucosamine and chondroitin sulfate, celecoxib 200 mg daily, or placebo) over 24 months. The primary outcome was a 20% reduction in pain over 24 months as measured by the Western Ontario and McMaster University Osteoarthritis Index (WOMAC). Secondary outcomes included an Outcome Measures in Rheumatology/Osteoarthritis Research Society International response and change from baseline in WOMAC pain and function. Over 2 years, none of the treatments (not even the positive control celecoxib) achieved a clinically important difference in WOMAC pain or function as compared with placebo. Adverse reactions were similar among treatment groups and serious adverse events were rare for all treatments.
Society and cultureEdit
Most chondroitin appears to be made from extracts of cartilaginous cow and pig tissues (cow trachea and pig ear and nose), but other sources such as shark, fish, and bird cartilage are also used. Since chondroitin is not a uniform substance, and is naturally present in a wide variety of forms, the precise composition of each supplement will vary. In fact, although many food supplement companies produce their products in compliance with human food processing Good Manufacturing Practice (GMP), most of them do not produce their products in compliance with the GMP regulations for pharmaceuticals, resulting in products without pharmaceutical requirements.
While it is a prescription or over-the-counter drug in 22 countries, chondroitin is regulated in the U.S. as a dietary supplement by the Food and Drug Administration. In Europe, chondroitin sulfate formulations are approved as drugs with evidenced efficacy and safety demonstrated by clinical trials in people with osteoarthritis. Adebowale et al. reported in 2000 that of 32 chondroitin supplements they analysed, only 5 were labeled correctly, and more than half contained less than 40% of the labeled amount. With the introduction of GMP regulations for dietary supplements in 2008, chondroitin sulfate preparations are subject in the US to mandatory labeling standards as well as testing requirements for identity, purity, strength, and composition. United States Pharmacopoeia (USP) testing standards for the identification and quantification of chondroitin are well-established.
There are no FDA regulations on chondroitin sulfate as a food additive, as it is recognized by the FDA as a component of food and is "generally recognized as safe". However, a proposed application of chondroitin sulfate dietary supplement as a means of preventing joint degeneration was highly scrutinized by the FDA, who stated:
For conventional foods, this evaluation involves considering whether the ingredient that is the source of the substance is generally recognized as safe (GRAS), approved as a food additive, or authorized by a prior sanction issued by FDA (see 21 CFR 101.70(f)). Dietary ingredients in dietary supplements, however, are not subject to the food additive provisions of the act (see section 201(s)(6) of the Act (21 U.S.C. § 321(s)(6)). Rather, they are subject to the adulteration provisions in section 402 of the Act (21 U.S.C. 342) and, if applicable, the new dietary ingredient provisions in section 413 of the Act (21 U.S.C. 350b), which pertain to dietary ingredients that were not marketed in the United States before October 15, 1994.— Letter Regarding the Relationship Between the Consumption of Glucosamine and/or Chondroitin Sulfate and a Reduced Risk of: Osteoarthritis; Osteoarthritis-related Joint Pain, Joint Tenderness, and Joint Swelling; Joint Degeneration; and Cartilage Deterioration
In the same letter, the FDA found that studies performed on the dietary supplement form of chondroitin sulfate were insufficient to substantiate claims that it is efficacious in the prevention of joint deterioration, and denied the request to be allowed to label the supplement as such. They further denied the request to market it as safe, given that no human clinical trials were done, citing that animal studies are not sufficient for the approval of a dietary supplement.
- Baeurle SA, Kiselev MG, Makarova ES, Nogovitsin EA (2009). "Effect of the counterion behavior on the frictional–compressive properties of chondroitin sulfate solutions". Polymer. 50 (7): 1805–1813. doi:10.1016/j.polymer.2009.01.066.
- Singh, JA; Noorbaloochi, S; MacDonald, R; Maxwell, LJ (28 January 2015). "Chondroitin for osteoarthritis". The Cochrane Database of Systematic Reviews. 1: CD005614. doi:10.1002/14651858.CD005614.pub2. PMC 4881293. PMID 25629804.
- American Academy of Orthopaedic Surgeons (February 2013), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American Academy of Orthopaedic Surgeons, retrieved 19 May 2013, which cites
- Jevsevar, DS; Brown, GA; Jones, DL; Matzkin, EG; Manner, PA; Mooar, P; Schousboe, JT; Stovitz, S; Sanders, JO; Bozic, KJ; Goldberg, MJ; Martin WR, 3rd; Cummins, DS; Donnelly, P; Woznica, A; Gross, L; American Academy of Orthopaedic Surgeons (Oct 16, 2013). "The American Academy of Orthopaedic Surgeons evidence-based guideline on: treatment of osteoarthritis of the knee, 2nd edition". The Journal of Bone and Joint Surgery. American Volume. 95 (20): 1885–6. doi:10.2106/00004623-201310160-00010. PMID 24288804.
- Clegg, Daniel O.; Reda, Domenic J.; Harris, Crystal L.; Klein, Marguerite A.; O'Dell, James R.; Hooper, Michele M.; Bradley, John D.; Bingham, Clifton O.; Weisman, Michael H.; Jackson, Christopher G.; Lane, Nancy E.; Cush, John J.; Moreland, Larry W.; Schumacher, H. Ralph; Oddis, Chester V.; Wolfe, Frederick; Molitor, Jerry A.; Yocum, David E.; Schnitzer, Thomas J.; Furst, Daniel E.; Sawitzke, Allen D.; Shi, Helen; Brandt, Kenneth D.; Moskowitz, Roland W.; Williams, H. James (23 February 2006). "Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis". New England Journal of Medicine. 354 (8): 795–808. doi:10.1056/NEJMoa052771. PMID 16495392.
- Richmond, J; Hunter, D; Irrgang, J; Jones, MH; Levy, B; Marx, R; Snyder-Mackler, L; Watters WC, 3rd; Haralson RH, 3rd; Turkelson, CM; Wies, JL; Boyer, KM; Anderson, S; St Andre, J; Sluka, P; McGowan, R; American Academy of Orthopaedic Surgeons (Sep 2009). "Treatment of osteoarthritis of the knee (nonarthroplasty)". The Journal of the American Academy of Orthopaedic Surgeons. 17 (9): 591–600. doi:10.5435/00124635-200909000-00006. PMC 3170838. PMID 19726743.
- 13. Hathcock JN, Shao a. Risk assessment for glucosamine and chondroitin sulfate. Regulatory Toxicology and Pharmacology, 2007; 47: 78-83
- Jordan KM; Recommendations Arden NK. EULAR (2003). "an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)". Ann Rheum Dis. 62 (12): 1145–1155. doi:10.1136/ard.2003.011742. PMC 1754382. PMID 14644851.
- Andermann G, Dietz M. The influence of the route of administration on the bioavailability of an endogenous macromolecule: chondroitin sulfate (CSA). Eur J Drug Metab Pharmacokinet 1982;7:11–6
- Monfort, J; Pelletier, JP; Garcia-Giralt, N; Martel-Pelletier, J (June 2008). "Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues". Annals of the Rheumatic Diseases. 67 (6): 735–40. doi:10.1136/ard.2006.068882. PMID 17644553.
- Conte, A; Palmieri, L; Segnini, D; Ronca, G (1991). "Metabolic fate of partially depolymerized chondroitin sulfate administered to the rat". Drugs Exp Clin Res. 17 (1): 27–33. PMID 1914833.
- Conte, A; de Bernardi, M; Palmieri, L; Lualdi, P; Mautone, G; Ronca, G (1991). "Metabolic fate of exogenous chondroitin sulfate in man". Arzneimittelforschung. 41 (7): 768–72. PMID 1772467.
- Conte, A; Volpi, N; Palmieri, L; Bahous, I; Ronca, G (1995). "Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate". Arzneimittelforschung. 45 (8): 918–25. PMID 7575762.
- Palmieri L, Conte A, Giovannini L, Lualdi P, Ronca G. Metabolic fate of exogenous chondroitin sulfate in the experimental animal" Arzneimittelforschung 1990;40:319-23.
- Ronca F, Palmieri L, Panicucci P, Ronca G. "Anti-inflammatory activity of chondroitin sulfate" Osteoarthritis and Cartilage 1998;6 Suppl A:14-21.
- Silbert JE, Sugumaran G (2002). "Biosynthesis of chondroitin/dermatan sulfate". IUBMB Life. 54 (4): 177–86. doi:10.1080/15216540214923. PMID 12512856.
- P. A. Levene; F. B. La Forge (1913). "On Chondroitin Sulphuric Acid". J. Biol. Chem. 15: 69–79. Free PDF online
- Chondroitin+sulfates at the US National Library of Medicine Medical Subject Headings (MeSH)
- Davidson EA, Meyer K (1954). "Chondroitin, a new mucopolysaccharide". J Biol Chem. 211 (2): 605–11. PMID 13221568. Free PDF online
- Barnhill JG, Fye CL, Williams DW, Reda DJ, Harris CL, Clegg DO (2006). "Chondroitin product selection for the glucosamine/chondroitin arthritis intervention trial". J Am Pharm Assoc (Wash DC). 46 (1): 14–24. doi:10.1331/154434506775268616. PMID 16529337.
- Zawisza, Julie (2008-03-19). "FDA Media Briefing on Heparin" (PDF). U.S. Food and Drug Administration. Retrieved 2008-04-23.
- Guerrini, M; Beccati, D; Shriver, Z; Naggi, A; Viswanathan, K; Bisio, A; Capila, I; Lansing, JC; Guglieri, S; Fraser, B; Al-Hakim, A; Gunay, NS; Zhang, Z; Robinson, L; Buhse, L; Nasr, M; Woodcock, J; Langer, R; Venkataraman, G; Linhardt, RJ; Casu, B; Torri, G; Sasisekharan, R (June 2008). "Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events". Nature Biotechnology. 26 (6): 669–75. doi:10.1038/nbt1407. PMC 3491566. PMID 18437154.
- Kishimoto, TK; Viswanathan, K; Ganguly, T; Elankumaran, S; Smith, S; Pelzer, K; Lansing, JC; Sriranganathan, N; Zhao, G; Galcheva-Gargova, Z; Al-Hakim, A; Bailey, GS; Fraser, B; Roy, S; Rogers-Cotrone, T; Buhse, L; Whary, M; Fox, J; Nasr, M; Dal Pan, GJ; Shriver, Z; Langer, RS; Venkataraman, G; Austen, KF; Woodcock, J; Sasisekharan, R (5 June 2008). "Contaminated heparin associated with adverse clinical events and activation of the contact system". The New England Journal of Medicine. 358 (23): 2457–67. doi:10.1056/NEJMoa0803200. PMC 3778681. PMID 18434646.
- Letter Regarding the Relationship Between the Consumption of Glucosamine and/or Chondroitin Sulfate and a Reduced Risk of: Osteoarthritis; Osteoarthritis-related Joint Pain, Joint Tenderness, and Joint Swelling; Joint Degeneration; and Cartilage Deterioration(Docket No. 2004P-0059). Addressed to John W. Emford, Esq. William K. Hubbard. Oct. 7, 2004. <http://www.fda.gov/food/ingredientspackaginglabeling/labelingnutrition/ucm073400.htm>
- Clegg, DO; et al. (2006). "Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis". N Engl J Med. 354 (8): 795–808. doi:10.1056/nejmoa052771. PMID 16495392.
- Sawitzke, Allen D.; Shi, Helen; Finco, Martha F.; Dunlop, Dorothy D.; Harris, Crystal L.; Singer, Nora G.; Bradley, John D.; Silver, David; Jackson, Christopher G.; Lane, Nancy E.; Oddis, Chester V.; Wolfe, Fred; Lisse, Jeffrey; Furst, Daniel E.; Bingham, Clifton O.; Reda, Domenic J.; Moskowitz, Roland W.; Williams, H. James; Clegg, Daniel O. (4 June 2010). "Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT". Annals of the Rheumatic Diseases. 69 (8): 1459–1464. doi:10.1136/ard.2009.120469. PMC 3086604. PMID 20525840.
- Barnhill, JG; Fye, CL; Williams, DW; Reda, DJ; Harris, CL; Clegg, DO (2006). "Chondroitin product selection for the glucosamine/chondroitin arthritis intervention trial". Journal of the American Pharmacists Association : JAPhA. 46 (1): 14–24. doi:10.1331/154434506775268616. PMID 16529337.
- "Questions and Answers: NIH Glucosamine/Chondroitin Arthritis Intervention Trial Primary Study", Backgrounder, National Center for Complementary and Integrative Medicine, 2006-01-02, retrieved 2013-10-17
- Vergés J, Castañeda-Hernández, G. On the bioavailability of oral chondroitin sulfate formulations: proposed criteria for bioequivalence studies. Proc. West. Pharmacol. Soc., 2004; 47: 50-53
- Adebowale AO Cox DS, Liang Z, Eddington ND (2000). "Analysis of glucosamine and chondroitin sulfate content in marketed products and the Caco-2 permeability of chondroitin sulfate raw materials". J Am Nutr Assoc. 3: 37–44. Archived from the original on April 7, 2006.
- Bhathal, A; Spryszak, M; Louizos, C; Frankel, G (2017). "Glucosamine and chondroitin use in canines for osteoarthritis: A review". Open Veterinary Journal. 7 (1): 36–49. doi:10.4314/ovj.v7i1.6. PMC 5356289. PMID 28331832.
- Bennett, D; Zainal Ariffin, SM; Johnston, P (January 2012). "Osteoarthritis in the cat: 2. how should it be managed and treated?". Journal of Feline Medicine and Surgery. 14 (1): 76–84. doi:10.1177/1098612X11432829. PMID 22247327.
- Goodrich, LR; Nixon, AJ (January 2006). "Medical treatment of osteoarthritis in the horse - a review". Veterinary Journal (London, England : 1997). 171 (1): 51–69. doi:10.1016/j.tvjl.2004.07.008. PMID 16427582.
- General Glucosamine and Chondroitin Sulfate information at Arthritis Foundation
- "Product Review: Joint Supplements (Glucosamine, Chondroitin, and MSM)" Summary of a Consumer Labs test of the actual composition of these supplements at consumerlabs.com
- "Glucosamine/Chondroitin Products Not Measuring Up", News report of the analysis of commercial supplements by Adebowale et al. at WebMD
- "Chondroitin Sulfate Manufacturing and Risk of Mad Cow Disease" by Winston Wicomb, Ph.D., September 24, 2002. Information on methods for extraction of chondroitin sulfate from cow trachea, at the Stone Clinic of San Francisco, at stoneclinic.com
- "Testing Status of Glucosamine Hydrochloride + Chondroitin Sulfate 09029", A thorough review of available information on the use of chondroitin sulfate in humans from the National Toxicology Program at National Institute of Environmental Health Sciences
- Chondroitin Sulfate, summary of information on the use of chondroitin sulfate from the publishers of the Physicians' Desk Reference.
- "Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)," ClinicalTrials.gov information on the purpose, design, and analysis of the study at clinicaltrials.gov
- "NIH News: Efficacy of Glucosamine and Chondroitin Sulfate May Depend on Level of Osteoarthritis Pain", Wednesday, February 22, 2006 at National Institutes of Health